Science, Discovery, Tech and Environment · 17 November 2026

WHO recommends two Bundibugyo Ebola vaccine candidates for DRC trial

Exam-focused facts from the 17 November 2026 current affairs briefing.

Key facts

  • The World Health Organization (WHO) has recommended adding two Ebola vaccine candidates, ChAdOx1 developed by the University of Oxford with the Serum Institute of India, and Moderna's mRNA-1469, to the ongoing Tumaini clinical trial in the Democratic Republic of the Congo (DRC).
  • This is the first time vaccines specifically designed against Bundibugyo virus, which is causing the current Ebola outbreak in the DRC, will be evaluated during an outbreak.
  • WHO's Technical Advisory Group on Candidate Vaccine Prioritization recommended both candidates based on preclinical and early clinical evidence; they will enter the trial after national approvals.
  • The Tumaini trial, led by the Institut National de Recherche Biomédicale of the DRC, tests multiple vaccine candidates in a single trial using a ring-vaccination approach, with four vaccination rings already in place.
  • Ervebo, the first vaccine being evaluated in the Tumaini trial against Bundibugyo virus, previously proved effective against Zaire ebolavirus in a landmark Guinea trial during the West Africa Ebola outbreak.
  • The WHO-sponsored PARTNERS trial, launched in July, is testing the monoclonal antibody MBP134, the antiviral remdesivir, or both for treating Bundibugyo virus disease, with maftivimab to be added soon, and a post-exposure prophylaxis study with Obeldesivir is also underway.
  • Vaccine trial results are expected in early 2027, while initial findings from the treatment trials are expected in the coming months.